Treatment News : Efavirenz Bests Nevirapine as First-Line Treatment in U.S.-Euro Study - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » June 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

June 19, 2012

Efavirenz Bests Nevirapine as First-Line Treatment in U.S.-Euro Study

by Tim Horn

Compared with nevirapine (Viramune), efavirenz (the active ingredient in Sustiva and a component of Atripla) appears to be associated with better survival, fewer AIDS-related opportunistic infections and a decreased likelihood of experiencing virologic failure among first-time treatment takers. These are the findings of a large cohort study published ahead of print by the journal AIDS.

“Our results have important clinical implications for patients initiating treatment without AIDS,” the authors write. “In these patients, we find that regimens containing efavirenz perform better than regimens containing nevirapine with respect to immunologic, virologic and clinical outcomes.”

Efavirenz and nevirapine are two of the most commonly prescribed NNRTIs around the world. For people starting therapy for the first time, the World Health Organization recommends either drug as a regimen component. The European AIDS Clinical Society and British HIV Association guidelines recommend both drugs, but do specify when each is preferred.

In the United States, Atripla remains the only “preferred” non-nucleoside reverse transcriptase inhibitor (NNRTI)-based option for first-time treatment takers. Nevirapine is considered a third-tier selection—it is an “acceptable” option, but both preferred and “alternative” NNRTI options (such as Complera, Edurant plus Epzicom, or Sustiva plus either Epzicom or Combivir) should be considered first.

While both agents have their limitations—efavirenz is generally not recommended during pregnancy and has been linked to sometimes disabling central nervous system problems; nevirapine should be avoided by people with high CD4 counts to reduce the risk of allergic reactions—is one necessarily more effective than the other?

One analysis of combined clinical trial data, along with cohort study results, indicate efavirenz is associated with better survival, viral load control and slower disease progression, compared with nevirapine. These studies, however, are limited in their interpretation, in that they weren’t necessarily limited to those starting HIV treatment for the first time or those in earlier stages of HIV disease.

To shed further light on these two agents, researchers with the HIV-CAUSAL Collaboration—consisting of six cohorts in Europe and the United States, all involving patients with universal access to care (for example, through the U.S. Veterans Administration)—looked at health outcomes among 14,857 people starting HIV therapy for the first time with an efavirenz-based regimen and 7,724 initiating treatment with a nevirapine-based regimen.

Pre-treatment CD4 cell counts and viral loads were similar between the two groups, though individuals treated with efavirenz were somewhat more likely to have a CD4 count below 200 cells (32.7 versus 28.2 percent) and to have a viral load in excess of 100,000 copies (35.8 versus 25.6 percent). Those starting treatment after 2003 and those with chronic hepatitis C infection were also more likely to initiate efavirenz than nevirapine.

Those on nevirapine were 54 percent more likely to have detectable viral loads after 12 months of treatment, compared with those who received efavirenz. They were also 26 percent more likely to develop an AIDS-defining illness or die. Looking at death alone as an outcome, this was 58 percent more likely among those who received nevirapine, compared with those who received efavirenz.

Those who received nevirapine also achieved a slightly smaller gain in CD4 counts after 12 months, with a 10 CD4 cell difference between the two groups.

Similar results were seen in separate analyses of the data focusing exclusively on men, those starting therapy in more recent years (2001 onward), patients initiating therapy with low CD4 cell counts and patients commencing HIV treatment with high viral loads.

“Both the meta-analysis of randomized trials and our analysis of observational data found an increase in mortality among initiators of nevirapine, compared with efavirenz, regimes,” the authors comment. “However, our result was more precise and directly applicable to HIV-infected individuals who are identified before an AIDS-defining illness is diagnosed. One possible explanation for our findings is that nevirapine regimens may be more frequently interrupted due to toxicities. If these patients switch to a second-line regimen that is less effective and harder to tolerate, nevirapine regimens will appear less effective than efavirenz regimens in an intention-to-treat analysis, particularly in later years.”

Search: efavirenz, sustiva, atripla, nevirapine, viramune, treatment naive, first-line, survival, mortality, progression, viral load, cd4 cells


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.